Alder BioPharmaceuticals is developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory diseases.



Alder BioPharmaceuticals Reports Third Quarter 2015 Financial and Operating Results> Read the story
Alder BioPharmaceuticals to Present at the Credit Suisse 24th Annual Healthcare Conference> Read the story



ALD1613 is a monoclonal antibody, discovered by Alder, which targets and inhibits the expression of ACTH.
Migraine is a significant cause of disability, generally affecting individuals between the ages of 20 and 50, their prime working years.
The Migraine Research Foundation estimates U.S. employers lose more than US$13 billion each year as a result of 113 million lost workdays due to migraine.
For the more than 11 million U.S. migraine patients who are candidates for migraine prevention, there are few therapeutic options to manage their disease.
According to the Migraine Research Foundation, every 10 seconds someone in the U.S. goes to the emergency room with a headache or migraine.
Approximately 36 million Americans suffer from migraines and according to the American Migraine Foundation, migraine is three times more common in women than men.
ALD403 is a monoclonal antibody, discovered by Alder, which targets CGRP for prevention of migraine. CGRP is a small protein that is involved in the transmission and heightened sensitivity to pain experienced in migraine.
Clazakizumab is a humanized monoclonal antibody, discovered by Alder, which binds to and inhibits IL-6. IL-6 is an important driver of the inflammatory response and is implicated in the transition from acute to chronic inflammation.
Cushing's disease is a rare but serious condition resulting from high levels of cortisol due to increased expression of ACTH produced by a pituitary tumor. It most commonly affects adults between 20 and 50 years of age.